ANI Pharmaceuticals Inc. (ANIP) said that it agreed to buy Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities, for $163.5 million. The deal price includes $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs of up to $46.5 million.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

ANI Pharmaceuticals Inc. (ANIP) said that it agreed to buy Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities, for $163.5 million. The deal price includes $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs of up to $46.5 million.

RTTNews | Mar 9, 2021 06:57AM EST

06:56 Tuesday, March 9, 2021 (RTTNews.com) - ANI Pharmaceuticals Inc. (ANIP) said that it agreed to buy Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities, for $163.5 million. The deal price includes $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs of up to $46.5 million.

ANI expects the transaction to be accretive to its adjusted non-GAAP earnings per share in the first 12 months after closing. It expects to close the deal in the second half of 2021.

ANI noted that it will finance the transaction with a new $300 million Term Loan B, issuance of $74 million in equity to the sellers, and a $25 million PIPE investment by Ampersand Capital Partners.

Read the original article on RTTNews ( https://www.rttnews.com/3175940/ani-pharma-to-buy-novitium-pharma-for-163-5-mln-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved